Solventum Corporation
NYSE:SOLVMedical - Care Facilities
-$2.00 today
- Market cap
- $14.70B
- Beta
- 0.75
- P/E (TTM)
- 9.1
- EPS (TTM)
- $8.22
Volume 0.76M
Average 1.70M
SOLV Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Solventum CorporationNYSE: SOLV
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q2 FY2026 stock-based compensation of $38M rose 11.8% year over year, behind the +23.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 25.5% from the prior quarter. Over 3 fiscal years it compounded at +63.3% a year.
Context
- Stock-based compensation amounted to 1.9% of revenue in FY2025, up 0.6 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +11.8% toward the trailing-twelve-month pace of +23.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 161M USD
- Year-over-year change
- +43.8%
- 4-year CAGR
- +43.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 161M | +43.8% |
| FY2024 | 2024-12-31 | 112M | +187.2% |
| FY2023 | 2023-12-31 | 39M | +5.4% |
| FY2022 | 2022-12-31 | 37M | -2.6% |
| FY2021 | 2021-12-31 | 38M | — |
Stock-Based Compensation vs competitors
How SOLV compares with its peers on the latest reported figures
- SOLV's LTM Jun 2026 stock-based compensation of $167M is the 2nd largest of the 10 companies compared; the peer median is $29M.
- Its year-over-year change of +23.7% is the 3rd highest of 9, against a peer median of -11.4%.
- Stock-based compensation amounts to 2.0% of revenue for SOLV, versus a peer median of 1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $204M | +270.9% | — | 1.0% | |
| LTM Jun 2026 | $167M | +23.7% | +63.3% | 2.0% | |
| LTM Jun 2026 | $115M | -5.7% | -5.8% | 1.0% | |
| LTM Sep 2026 | $45.39M | +5.4% | +34.1% | 2.8% | |
| LTM Jun 2026 | $41.12M | -19.2% | +15.7% | 1.9% | |
| LTM Jun 2026 | $29M | -17.1% | — | 0.2% | |
| LTM Mar 2026 | $16M | -57.9% | -17.6% | 0.4% | |
| LTM Oct 2026 | $2.3M | -91.5% | +7.2% | 0.1% | |
| LTM Mar 2026 | $411K | +58.7% | +26.8% | 1.1% | |
| LTM Jul 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding SOLV) | $29M | -11.4% | +11.4% | 1.0% | |
Competitors are the stored peer set for SOLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.46B | 1.34B | 1.35B | 479M | 1.56B |
| Depreciation & Amortization | 597M | 578M | 561M | 555M | 489M |
| Deferred Income Tax | (34M) | (141M) | (142M) | (155M) | (120M) |
| Stock-Based Compensation | 38M | 37M | 39M | 112M | 161M |
| Change in Working Capital | 67M | (202M) | 126M | 160M | (119M) |
| Accounts Receivables | (1M) | (32M) | (129M) | 276M | 78M |
| Inventory | (136M) | (82M) | 23M | (132M) | (139M) |
| Accounts Payables | 68M | 25M | 105M | 266M | 104M |
| Other Working Capital | 136M | (113M) | 127M | (250M) | (162M) |
| Other Non-Cash Items | 74M | 64M | (15M) | 34M | (1.6B) |
| Operating Cash Flow | 2.2B | 1.68B | 1.92B | 1.19B | 369M |
| Capital Expenditures | (277M) | (251M) | (290M) | (380M) | (379M) |
| Acquisitions (Net) | 0 | 0 | 60M | 0 | (696M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1M) | (2M) | 0 | 0 | 3.87B |
| Investing Cash Flow | (278M) | (253M) | (230M) | (380M) | 2.8B |
| Debt Repayment | 0 | 0 | 0 | 8B | (3.07B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.96B) | (1.46B) | (1.55B) | (8.24B) | 13M |
| Financing Cash Flow | (1.96B) | (1.46B) | (1.55B) | (240M) | (3.06B) |
| Effect of Forex Changes | 3M | 4M | 0 | 3M | 7M |
| Net Change in Cash | (33M) | (30M) | 133M | 568M | 116M |
| Free Cash Flow | 1.93B | 1.43B | 1.63B | 805M | (10M) |
Solventum Corporation
NYSE:SOLV
Intrinsic Alpha fair value
Locked
Current Price
$86.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.